Clinic Roundup
Psivida Corp., of Watertown, Mass., said interim data from a three-year, investigator-sponsored Phase I/II study of its injectable micro-insert in patients with posterior uveitis showed none of the treated eyes had a recurrence of uveitis through the first 12 months of enrollment, and inflammation was reduced in all treated eyes.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.